Default company panoramic image

American Gene Technologies

American Gene Technologies is a leader in the application of viral vectors to the treatment of serious human diseases.

  • Stage Concept Only
  • Industry Biotechnology
  • Location Rockville, MD, USA
  • Currency USD
  • Website

Company Summary

American Gene Technologies (AGT) collaborates with universities to leverage and commercialize viral vector delivery and genetics IP in multi-billion dollar markets. Leading genetic researchers utilize AGT's proprietary gene delivery platform to prove in vivo efficacy of re-regulating gene expression for the diseases within their research expertise, and enter drug candidates into clinical testing in order to monetize their research and IP assets.


  • Default avatar
    Jeffrey A Galvin
    CEO/Founder, Chairman

    Mr. Galvin founded the company after meeting Dr. Brady at the National Institutes of Health and learning about gene therapeutic vectors that were being developed. Mr. Galvin's previous experience was several successful Silicon Valley startups and real-estate investments. Mr. Galvin served as Managing Partner at Onemart International Investments LLC. and came out of early retirement to fund, found and manage American Gene Technologies.

  • Default avatar
    Roscoe O Brady, MD, PhD
    Scientific Leader, Board Member

    Dr. Brady is responsible for the first ever developed gene therapeutic (enzyme-replacement therapy) which lead to the highly successful growth of Genzyme Corporation based on Dr. Brady's cure for Gaucher's Disease. Dr. Brady has been nominated several times for the Nobel Prize in Medicine, he is the 2008 recipient of the Presidential National Medal of Technology, a Lasker Fellow and Scientist Emeritus at NIH for his many scientific achievements.